Spencer Feldman

Overall survival data in the IMbrave152/SKYSCRAPER-14 study are not anticipated to show statistical significance.

Patients with neuropathy experienced a longer PFS with enfortumab vedotin vs those without neuropathy, skin rash, or hyperglycemia.

The phase 3 ZEST trial discovered that, with low ctDNA at baseline, the recurrence-free interval is longer for patients with triple-negative breast cancer.

Time to next treatment was slightly higher with elacestrant for patients with HR+/HER2–, ESR1-mutant breast cancer vs PFS in a phase 3 trial.